rtki cpd and pentetic acid

rtki cpd has been researched along with pentetic acid in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Brechbiel, MW; Burgess, AW; Hall, C; Johns, TG; Kelly, MP; Lee, FT; Mountain, AJ; Nice, EC; Rigopoulos, A; Scott, AM; Smyth, FE1
Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE1

Other Studies

3 other study(ies) available for rtki cpd and pentetic acid

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pentetic Acid; Protein-Tyrosine Kinases; Quinazolines; Radioimmunotherapy; Radiopharmaceuticals; Signal Transduction; Time Factors; Tissue Distribution; Tyrphostins; Yttrium Radioisotopes

2005
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    The Prostate, 2009, Jan-01, Volume: 69, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays

2009